Wells Fargo’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Wells Fargo’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-4,500	Closed	–	–	6685
2016 Q3	$0	Buy	+4,500	New	+$981	﹤0.01%	6522
2016 Q2	–	Sell	-1	Closed	–	–	6577
2016 Q1	$0	Hold	1	–	–	﹤0.01%	6640
2015 Q4	$0	Sell	1 -2,000	-100%	-$948	﹤0.01%	6606
2015 Q3	$1K	Hold	2,001	–	–	﹤0.01%	6135
2015 Q2	$1K	Hold	2,001	–	–	﹤0.01%	6294
2015 Q1	$2K	Sell	2,001 -1,000	-33%	-$824	﹤0.01%	6007
2014 Q4	$3K	Hold	3,001	–	–	﹤0.01%	5982
2014 Q3	$3K	Sell	3,001 -5,000	-62%	-$4.85K	﹤0.01%	5963
2014 Q2	$7K	Buy	+8,001	New	+$9.59K	﹤0.01%	5751

Other funds holding PVCT

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

Wells Fargo's PVCT Position: Q4 2016 in Review

Wells Fargo sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q4 2016, closing a stake of 4,500 shares.

Wells Fargo first reported a position in PVCT in Q2 2014 and held it in 9 quarters. The position peaked at $7K in Q2 2014. 8 funds tracked by Wall St. Rank hold PVCT as of Q4 2016.

Wells Fargo reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q4 2016 after selling out during the quarter.
Wells Fargo sold 4,500 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q4 2016.
Wells Fargo first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2014 and held it in 9 quarters.
Wells Fargo's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $7K in Q2 2014.
8 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2016.

Based on Wells Fargo's 13F filing for Q4 2016, filed 1 Feb 2017.